Skip to main
OCS
OCS logo

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG's financial outlook remains positive, supported by an increase in R&D expenses to CHF 52.1 million for FY24, reflecting the company's commitment to advancing clinical trials for its key candidates OCS-01, OCS-02, and OCS-05. The estimated market value of the firm has risen to $1.41 billion, highlighting investor confidence amid ongoing development and progress in their pipeline, particularly with OCS-01, which is seeing advancements in multiple indications. Additionally, the planned launch of the new Phase 2b/3 study by late 2025 or early 2026 reinforces the company's strategic focus on innovative therapies in eye care, contributing to its favorable market positioning.

Bears say

Oculis Holding faces significant challenges due to potential delays in clinical development, regulatory approvals, and commercialization timelines, which could result in extended development periods and increased costs. The company's financial health is concerning, highlighted by a substantial net loss of CHF 85.8 million in 2024, which raises questions about its sustainability and ability to fund ongoing projects. Additionally, market competition from existing and emerging therapies may hinder Oculis' market penetration and pricing power, further impacting the commercialization prospects of its key candidates, including OCS-01, OCS-02, and OCS-05.

OCS has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 6 analysts, OCS has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.